OA
UNCY icon

Oxbow Advisors’s Unicycive Therapeutics UNCY Stock Holding History

Oxbow Advisors’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,186
Closed -$15.2K – 220
2023
Q2 		$15.2K Hold
1,186
– – ﹤0.01% 209
2023
Q1 		$24.9K Buy
+1,186
New +$11.8K ﹤0.01% 198

Other funds holding UNCY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
TCM
Tandem Capital Management Woodcliff Lake, New Jersey $200M AUM 25.01% 1-Year Est. Return

Oxbow Advisors's UNCY Position: Q3 2023 in Review

Oxbow Advisors sold out of Unicycive Therapeutics (UNCY) in Q3 2023, closing a stake of 1,186 shares — an estimated $15.2K sold.

Oxbow Advisors first reported a position in UNCY in Q1 2023 and held it in 2 quarters. The position peaked at $24.9K in Q1 2023. 16 funds tracked by Wall St. Rank hold UNCY as of Q3 2023.

  • Oxbow Advisors reported no remaining Unicycive Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Oxbow Advisors sold 1,186 Unicycive Therapeutics shares in Q3 2023, an estimated $15.2K.
  • Oxbow Advisors first reported a position in Unicycive Therapeutics in Q1 2023 and held it in 2 quarters.
  • Oxbow Advisors's Unicycive Therapeutics position peaked at $24.9K in Q1 2023.
  • 16 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q3 2023.

Based on Oxbow Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.